Lb Pharmaceuticals (LBRX) Non-Current Assets (2024 - 2026)

Lb Pharmaceuticals has reported Non-Current Assets for 3 years, with the latest figure at $4.4 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets changed N/A year-over-year to $4.4 million; the trailing twelve-month figure through Mar 2026 stood at $17.9 million (changed N/A YoY), and the FY2025 full-year result was $4.5 million, down 3.29% from the prior year.
• Non-Current Assets for Q1 2026 stood at $4.4 million, down from $4.5 million in the prior quarter.
• The five-year high for Non-Current Assets was $4.7 million in Q4 2024, with the low at $4.3 million in Q3 2025.
• Average Non-Current Assets over 3 years is $4.5 million, with a median of $4.5 million recorded in 2025.
• Peak annual rise in Non-Current Assets reached 3.29% in 2025, while the deepest fall reached 3.29% in 2025.
• Tracing LBRX's Non-Current Assets over 3 years: stood at $4.7 million in 2024, then fell by 3.29% to $4.5 million in 2025, then slipped by 2.09% to $4.4 million in 2026.
• The last three Non-Current Assets figures came in at $4.4 million (Q1 2026), $4.5 million (Q4 2025), and $4.3 million (Q3 2025), per Business Quant data.

Peer Comparison